about
Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implicationsChromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.Efficacy and safety of stem cell mobilization with cyclophosphamide plus etoposide versus cyclophosphamide alone.Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor.HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple MyelomaCentral nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.The Analysis of the Relationship between Multiple Myeloma Cells and Their MicroenvironmentRheological properties of erythrocytes in patients infected with Clostridium difficile.The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.New drugs in multiple myeloma - role of carfilzomib and pomalidomide.The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series.n-3 Fatty acids as resolvents of inflammation in the A549 cells.Percutaneous Vertebroplasty for Pathological Vertebral Compression Fractures Secondary to Multiple Myeloma--Medium-Term and Long-Term Assessment of Pain Relief and Quality of Life.Identification of miRSNPs associated with the risk of multiple myeloma.Resolvin D1 down-regulates CYP1A1 and PTGS2 gene in the HUVEC cells treated with benzo(a)pyrene.Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma - Polish retrospective multicenter analysis.Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.IgM myeloma: A multicenter retrospective study of 134 patients.Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.State of oral mucosa as an additional symptom in the course of primary amyloidosis and multiple myeloma disease.Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons.Plasma fatty acid profile in multiple myeloma patients.Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.Erythrocyte membrane fatty acids in multiple myeloma patients.Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.[Hepatocyte growth factor: from diagnosis to clinical application].[Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.Bortezomib for the treatment of multiple myeloma.Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group.Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.High expression of CC chemokine receptor 5 (CCR5) promotes disease progression in patients with B-cell non-Hodgkin lymphomas.[Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].Blocking MET receptor signaling in multiple myeloma cells in vitro and in vivo.
P50
Q26774558-1A91B372-9827-4054-A7AB-A6C1D0A6F06FQ31154933-F901C2C4-3ACB-43F1-86E1-A892B1109259Q33415539-F617B996-48C3-4111-A541-DF16FA9C04E7Q33431014-12B68AB4-603F-44D7-B2D6-7E0F4EEB321AQ33789416-45A408D6-113B-4DCF-940C-D4ACC5F1F1BBQ33794361-932D8CF7-0440-4ED3-9969-5FC79C96CD4FQ33885555-CBEAC30B-FC2E-48B9-B421-E7C88B7BC60CQ34671809-77F0C447-FFE3-4261-89C8-A85610ABF044Q34791709-08F3D37C-3626-4D9B-9432-03184490DF10Q35532278-4AFFDBDC-17C0-4BFD-9D5C-A204EAF8EA49Q36673465-495DAFBA-98DE-4565-8EBE-6250210A9420Q36929923-4B63375C-29B5-4610-B0A9-091A64948881Q37644812-D74C5A3B-788E-4734-9DEB-3644EBE007CBQ38216018-462E6A02-A03A-462E-920B-C34B4030DE2AQ38231358-E7B893A4-30DF-4E8D-8666-EA8A58AA1422Q38723750-B0AF1E24-30D2-4C75-AB84-9B66DB9A368CQ38880083-03759550-7BDF-4A4C-A4C3-C9FAF6BC150FQ39182072-BA9AF55B-DF32-4395-818B-E6676BD2BF5CQ39309897-B4C9A512-D3F9-4A23-90B7-F9C847F8479BQ39642549-477327F5-FAA6-4A2B-A6C8-FEA7D005A4F0Q40046482-B6875C92-A3EF-476B-B1D9-9B23F0F19DD0Q40149390-44EB2C12-C668-4305-BE21-33D02544DD5AQ40255441-795A5CFF-2113-4E43-BCD5-13EF920681E9Q40561960-2EF4A909-050A-47AE-90FD-607CDC52C4F4Q41155299-17B2DB63-003B-448E-B5AC-2225605AA433Q41247442-E2260DFA-1AC4-4C71-B219-4DBF9138D4F6Q41493552-35F77E42-DD09-4812-AFBE-CC550FFBE49AQ41552459-DF6A1514-A48F-45F3-A4CE-FE65FB239ABCQ41752196-D774F111-23DA-40E7-AC3D-74FD518FCBC8Q44554207-B50DCE5C-4408-4D63-80B7-2D8CB4C406F0Q44770542-7AD44363-18F4-47C2-90D5-AD6B03DE2DE4Q44770614-EEAF617C-8FD7-4D3B-8AEA-36ABE9092F96Q46028356-C9FB24A0-AA9F-4A53-A6AC-BC8DCBEF1B69Q47101456-56023210-4ACC-471B-A86B-86F9460AE0FAQ47604607-BC98D04B-BE9B-4DF6-A351-2FB6CBBCD010Q47967442-09EB5432-D97D-4952-8556-E7C833E4A063Q48283707-896E6388-FEA0-4680-9FF3-6932515DF67FQ49886634-099259D8-FE67-4335-9D82-BA8D42FF3CFEQ51304388-719A7CF8-C31F-4607-BB20-3AA52BAD65B4Q51742418-AEAAAF7E-3C10-4197-B52D-78AD4CEBCF4C
P50
description
Polish hematologist
@en
onderzoeker
@nl
polski lekarz, hematolog
@pl
name
Artur Jurczyszyn
@ast
Artur Jurczyszyn
@ca
Artur Jurczyszyn
@cs
Artur Jurczyszyn
@en
Artur Jurczyszyn
@es
Artur Jurczyszyn
@gl
Artur Jurczyszyn
@hr
Artur Jurczyszyn
@hsb
Artur Jurczyszyn
@it
Artur Jurczyszyn
@nl
type
label
Artur Jurczyszyn
@ast
Artur Jurczyszyn
@ca
Artur Jurczyszyn
@cs
Artur Jurczyszyn
@en
Artur Jurczyszyn
@es
Artur Jurczyszyn
@gl
Artur Jurczyszyn
@hr
Artur Jurczyszyn
@hsb
Artur Jurczyszyn
@it
Artur Jurczyszyn
@nl
prefLabel
Artur Jurczyszyn
@ast
Artur Jurczyszyn
@ca
Artur Jurczyszyn
@cs
Artur Jurczyszyn
@en
Artur Jurczyszyn
@es
Artur Jurczyszyn
@gl
Artur Jurczyszyn
@hr
Artur Jurczyszyn
@hsb
Artur Jurczyszyn
@it
Artur Jurczyszyn
@nl
P106
P1412
P1559
Artur Jurczyszyn
@pl
P21
P27
P31
P3124
P496
0000-0001-9796-8365